Next Article in Journal
Astragalus-Containing Traditional Chinese Medicine, with and without Prescription Based on Syndrome Differentiation, Combined with Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systemic Review and Meta-Analysis
Previous Article in Journal
Reduction in Membranous Immunohistochemical Staining for the Intracellular Domain of Epithelial Cell Adhesion Molecule Correlates with Poor Patient Outcome in Primary Colorectal Adenocarcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 3
10.3747/co.23.2988
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration

by
W.K. Evans
1,*,
W.M. Flanagan
2,
A.B. Miller
3,
J.R. Goffin
1,
S. Memon
4,
N. Fitzgerald
4 and
M.C. Wolfson
5
1
McMaster University, Hamilton, ON, Canada
2
Statistics Canada, Ottawa, ON, Canada
3
Dalla Lana School of Public Health, Toronto, ON, Canada
4
Canadian Partnership Against Cancer, Toronto, ON, Canada
5
University of Ottawa, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 179-187; https://doi.org/10.3747/co.23.2988
Submission received: 11 March 2016 / Revised: 12 April 2016 / Accepted: 12 May 2016 / Published: 1 June 2016

Abstract

Background: Low-dose computed tomography (LDCT) screening has been shown to reduce mortality from lung cancer; however, the optimal screening duration and “at risk” population are not known. Methods: The Cancer Risk Management Model developed by Statistics Canada for the Canadian Partnership Against Cancer includes a lung screening module based on data from the U.S. National Lung Screening Trial (NLST). The base-case scenario reproduces NLST outcomes with high fidelity. The impact in Canada of annual screening on the number of incident cases and life-years gained, with a wider range of age and smoking history eligibility criteria and varied participation rates, was modelled to show the magnitude of clinical benefit nationally and by province. Life-years gained, costs (discounted and undiscounted), and resource requirements were also estimated. Results: In 2014, 1.4 million Canadians were eligible for screening according to NLST criteria. Over 10 years, screening would detect 12,500 more lung cancers than the expected 268,300 and would gain 9200 life-years. The computed tomography imaging requirement of 24,000–30,000 at program initiation would rise to between 87,000 and 113,000 by the 5th year of an annual NLST-like screening program. Costs would increase from approximately $75 million to $128 million at 10 years, and the cumulative cost nationally over 10 years would approach $1 billion, partially offset by a reduction in the costs of managing advanced lung cancer. Conclusions: Modelling various ways in which LDCT might be implemented provides decision-makers with estimates of the effect on clinical benefit and on resource needs that clinical trial results are unable to provide.
Keywords: Lung cancer; screening; low-dose computed tomography; modelling; nlst; Canada Lung cancer; screening; low-dose computed tomography; modelling; nlst; Canada

Share and Cite

MDPI and ACS Style

Evans, W.K.; Flanagan, W.M.; Miller, A.B.; Goffin, J.R.; Memon, S.; Fitzgerald, N.; Wolfson, M.C. Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. Curr. Oncol. 2016, 23, 179-187. https://doi.org/10.3747/co.23.2988

AMA Style

Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, Wolfson MC. Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. Current Oncology. 2016; 23(3):179-187. https://doi.org/10.3747/co.23.2988

Chicago/Turabian Style

Evans, W.K., W.M. Flanagan, A.B. Miller, J.R. Goffin, S. Memon, N. Fitzgerald, and M.C. Wolfson. 2016. "Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration" Current Oncology 23, no. 3: 179-187. https://doi.org/10.3747/co.23.2988

APA Style

Evans, W. K., Flanagan, W. M., Miller, A. B., Goffin, J. R., Memon, S., Fitzgerald, N., & Wolfson, M. C. (2016). Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. Current Oncology, 23(3), 179-187. https://doi.org/10.3747/co.23.2988

Article Metrics

Back to TopTop